Genetic factors affecting drug disposition in Asian cancer patients

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 12, 2015, Pages 1879-1892

  Syn, Nicholas Li Xun ^a   Yong, Wei Peng ^a,b   Lee, Soo Chin ^a,b   Goh, Boon Cher ^a,b,c  

^a National University Cancer Institute   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ADME; adverse drug events; Asian cancer patients; chemotherapy; drug disposition; pharmacoethnicity; pharmacogenetics; pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CIS ACTING ELEMENT; TRANS ACTING FACTOR; CARRIER PROTEIN; ENZYME;

ANCESTRY GROUP; ASIAN; CANCER PATIENT; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; ETHNICITY; GEOGRAPHY; HEREDITY; HISTORY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; METABOLISM; MUTATION; NEOPLASMS; PHENOTYPE;

ALLELES; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ENZYMES; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 84949323260     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1108964     Document Type: Review

References (99)

1. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348: 538-549. DOI: 10.1056/NEJMra020526.
2. Kimchi-Sarfaty C, Oh JM, Kim I-W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007; 315: 525-528. DOI: 10.1126/science.1135308.
3. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV., et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007; 67: 9609-9612. DOI: 10.1158/0008-5472.CAN-07-2377.
4. Wang D, Johnson AD, Papp AC., et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15: 693-704.
5. ODonnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009; 15: 4806-4814. DOI: 10.1158/1078-0432.CCR-09-0344.
6. Rodríguez-Antona C, Niemi M, Backman JT., et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008; 8: 268-277. DOI: 10.1038/sj.tpj.6500482.
7. ICoHs C. International Conference Harmonization (ICH) Topic E 5 (R1): ethnic factors in the acceptability of foreign clinical data. Fed Regist. 1998; 63: 31790-31796.
8. Tan S-H, Lee S-C, Goh B-C., et al. Pharmacogenetics in breast cancer therapy. Clin Cancer Res. 2008; 14: 8027-8041. DOI: 10.1158/1078-0432.CCR-08-0993.
9. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet. 2003; 4: 293-340. DOI: 10.1146/annurev.genom.4.070802.110226.
10. Tishkoff SA, Kidd KK. Implications of biogeography of human populations for "race" and medicine. Nat Genet. 2004; 36: S21-S27. DOI: 10.1038/ng1438.
11. Bamshad M, Wooding S, Salisbury BA., et al. Deconstructing the relationship between genetics and race. Nat Rev Genet. 2004; 5: 598-609. DOI: 10.1038/nrg1401.
12. Barbujani G, Magagni A, Minch E., et al. An apportionment of human DNA diversity. Proc Natl Acad Sci USA. 1997; 94: 4516-4519.
13. Sistonen J, Sajantila A, Lao O., et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007; 17: 93-101. DOI: 10.1097/01.fpc.0000239974.69464.f2.
14. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005; 5: 6-13. DOI: 10.1038/sj.tpj.6500285.
15. Lim H-S, Ju Lee H, Seok Lee K., et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25: 3837-3845. DOI: 10.1200/JCO.2007.11.4850.
16. Regan MM, Leyland-Jones B, Bouzyk M., et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012; 104: 441-451. DOI: 10.1093/jnci/djs125.
17. Lim JSL, Chen XA, Singh O., et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011; 71: 737-750. DOI: 10.1111/j.1365-2125.2011.03905.x.
18. Kim I-W, Kim KI, Chang H-J., et al. Ethnic variability in the allelic distribution of pharmacogenes between Korean and other populations. Pharmacogenet Genomics. 2012; 22: 829-836. DOI: 10.1097/FPC.0b013e328358dd70.
19. Teo Y-Y, Sim X, Ong RTH., et al. Singapore Genome Variation Project: a haplotype map of three Southeast Asian populations. Genome Res. 2009; 19: 2154-2162. DOI: 10.1101/gr.095000.109.
20. Brunham LR, Chan SL, Li R., et al. Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 2014; 14: 555-563. DOI: 10.1038/tpj.2014.22.
21. Henn BM, Cavalli-Sforza LL, Feldman MW. The great human expansion. Proc Natl Acad Sci USA. 2012; 109: 17758-17764. DOI: 10.1073/pnas.1212380109.
22. Majumder PP. The human genetic history of South Asia. Curr Biol. 2010; 20: R184-R187. DOI: 10.1016/j.cub.2009.11.053.
23. Xing J, Watkins WS, Hu Y., et al. Genetic diversity in India and the inference of Eurasian population expansion. Genome Biol. 2010; 11: R113. DOI: 10.1186/gb-2010-11-11-r113.
24. Wang H, Ding K, Zhang Y., et al. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics. 2007; 17: 667-678. DOI: 10.1097/FPC.0b013e328165249f.
25. Xue Y, Sun D, Daly A., et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008; 83: 337-346. DOI: 10.1016/j.ajhg.2008.08.004.
26. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med. 2003; 348: 1166-1170. DOI: 10.1056/NEJMsb022863.
27. Ng PC, Zhao Q, Levy S., et al. Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther. 2008; 84: 306-309. DOI: 10.1038/clpt.2008.114.
28. Lee S-C, Ng S-S, Oldenburg J., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006; 79: 197-205. DOI: 10.1016/j.clpt.2005.11.006.
29. Matsusaka S, Lenz H-J. Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin Drug Metab Toxicol. 2015; 11: 811-821. DOI: 10.1517/17425255.2015.1027684.
30. Koizumi W, Tanabe S, Saigenji K., et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003; 89: 2207-2212. DOI: 10.1038/sj.bjc.6601413.
31. Chuah B, Goh B-C, Lee S-C., et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011; 102: 478-483. DOI: 10.1111/j.1349-7006.2010.01793.x.
32. Haller DG, Cassidy J, Clarke SJ., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008; 26: 2118-2123. DOI: 10.1200/JCO.2007.15.2090.
33. Van Zuylen L, Verweij J, Nooter K., et al. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res. 2000; 6: 2598-2603.
34. Hoffmeyer S, Burk O, von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000; 97: 3473-3478. DOI: 10.1073/pnas.050585397.
35. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem. 2004; 4: 1385-1398.
36. Hillgren KM, Keppler D, Zur AA., et al. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther. 2013; 94: 52-63. DOI: 10.1038/clpt.2013.74.
37. Ameyaw MM, Regateiro F, Li T., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001; 11: 217-221.
38. Lai Y, Varma M, Feng B., et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin Drug Metab Toxicol. 2012; 8: 723-743. DOI: 10.1517/17425255.2012.678048.
39. Herve F, Gomas E, Duche JC., et al. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol. 1993; 36: 241-249.
40. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011; 30: 287-292.
41. Blain PG, Mucklow JC, Rawlins MD., et al. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol. 1985; 20: 500-502.
42. Murray GI, Taylor MC, McFadyen MC., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997; 57: 3026-3031.
43. Rochat B, Morsman JM, Murray GI., et al. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001; 296: 537-541.
44. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003; 22: 7496-7511. DOI: 10.1038/sj.onc.1206950.
45. Soo RA, Wang LZ, Ng SS., et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 2009; 63: 121-127. DOI: 10.1016/j.lungcan.2008.04.010.
46. De Morais SM, Wilkinson GR, Blaisdell J., et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269: 15419-15422.
47. Scott SA, Sangkuhl K, Stein CM., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94: 317-323. DOI: 10.1038/clpt.2013.105.
48. De Morais SM, Wilkinson GR, Blaisdell J., et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994; 46: 594-598.
49. Yamamoto N, Murakami H, Nishina T., et al. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol. 2013; 24: 1653-1659. DOI: 10.1093/annonc/mdt014.
50. Yang JJ, Landier W, Yang W., et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015; 33: 1235-1242. DOI: 10.1200/JCO.2014.59.4671.
51. Yang S-K, Hong M, Baek J., et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014; 46: 1017-1020. DOI: 10.1038/ng.3060.
52. Fan L, Goh B-C, Wong C-I., et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics. 2008; 18: 621-631. DOI: 10.1097/FPC.0b013e328301a869.
53. Xie H-J, Yasar U, Lundgren S., et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003; 3: 53-61. DOI: 10.1038/sj.tpj.6500157.
54. Nakajima M, Komagata S, Fujiki Y., et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007; 17: 431-445. DOI: 10.1097/FPC.0b013e328045c4fb.
55. Xiang X, Jada SR, Li HH., et al. Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics. 2006; 16: 683-691. DOI: 10.1097/01.fpc.0000230420.05221.71.
56. Nozawa T, Minami H, Sugiura S., et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005; 33: 434-439. DOI: 10.1124/dmd.104.001909.
57. Alvarellos ML, Lamba J, Sangkuhl K., et al. PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics. 2014; 24: 564-574. DOI: 10.1097/FPC.0000000000000086.
58. Wong AL-A, Yap H-L, Yeo W-L., et al. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics Proteomics. 2011; 8: 255-259.
59. Owen RP, Gray JH, Taylor TR., et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics. 2005; 15: 83-90.
60. Suthandiram S, Gan G-G, Zain SM., et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014; 15: 1479-1494. DOI: 10.2217/pgs.14.97.
61. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003; 197: 1279-1289. DOI: 10.1084/jem.20030044.
62. Wong AL-A, Wang L, Wong F, et al. Prospective, non-randomised, open-label study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy. [Internet]. ECC 2015 (18th ECCO-40th ESMO) Annual Congress; 2015 Sep 25-29; Vienna. Abstract number: 1889. [cited 2015 Oct 24]. Available from: http://www.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=20436
63. Wong N-S, Seah EZ, Wang L-Z., et al. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics. 2011; 21: 760-768. DOI: 10.1097/FPC.0b013e32834a8639.
64. Sun D, Chen G, Dellinger RW., et al. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics. 2010; 20: 575-585. DOI: 10.1097/FPC.0b013e32833b04af.
65. Garte S, Gaspari L, Alexandrie AK., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001; 10: 1239-1248.
66. Khrunin AV, Moisseev A, Gorbunova V., et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010; 10: 54-61. DOI: 10.1038/tpj.2009.45.
67. Hsieh KP, Lin YY, Cheng CL., et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001; 29: 268-273.
68. Yang X, Zhang B, Molony C., et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20: 1020-1036. DOI: 10.1101/gr.103341.109.
69. Yang H-C, Lin C-W, Chen C-W., et al. Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogenetics. BMC Genomics. 2014; 15: 319. DOI: 10.1186/1471-2164-15-319.
70. Cooper DN. Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. Hum Genomics. 2010; 4: 284-288.
71. Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum Genomics. 2010; 4: 402-405.
72. Singh O, Chan JY, Lin K., et al. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One. 2012; 7: e51771. DOI: 10.1371/journal.pone.0051771.
73. Goswami S, Gong L, Giacomini K., et al. PharmGKB summary: very important pharmacogene information for SLC22A1. Pharmacogenet Genomics. 2014; 24: 324-328. DOI: 10.1097/FPC.0000000000000048.
74. Shu Y, Sheardown SA, Brown C., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117: 1422-1431. DOI: 10.1172/JCI30558.
75. Aquilante CL, Niemi M, Gong L., et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013; 23: 721-728. DOI: 10.1097/FPC.0b013e3283653b27.
76. Saito Y, Katori N, Soyama A., et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics. 2007; 17: 461-471. DOI: 10.1097/FPC.0b013e32805b72c1.
77. Lamba J, Hebert JM, Schuetz EG., et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012; 22: 555-558. DOI: 10.1097/FPC.0b013e328351d47f.
78. Kuehl P, Zhang J, Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27: 383-391. DOI: 10.1038/86882.
79. Saeki M, Saito Y, Nakamura T., et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat. 2003; 21: 653. DOI: 10.1002/humu.9147.
80. Balram C, Zhou Q, Cheung YB., et al. CYP3A5 3 and 6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003; 59: 123-126. DOI: 10.1007/s00228-003-0594-2.
81. Kai Y, Hamada A, Sasaki J., et al. Abstract 5459: Association of CYP1A1 and CYP3A5 polymorphisms with pharmacokinetics of erlotinib in patients with non-small cell lung cancer. 102nd Annual Meeting American Association for Cancer Research; vol. 71, p. Abstract nr 5459. DOI: 10.1158/1538-7445.AM2011-5459.
82. Goh BC, Lee SC, Wang LZ., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002; 20: 3683-3690. DOI: 10.1200/JCO.2002.01.025.
83. Iyer L, Das S, Janisch L., et al. UGT1A1 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43-47.
84. Hsieh T-Y, Shiu T-Y, Huang S-M., et al. Molecular pathogenesis of Gilberts syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet Genomics. 2007; 17: 229-236. DOI: 10.1097/FPC.0b013e328012d0da.
85. Barbarino JM, Haidar CE, Klein TE., et al. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014; 24: 177-183. DOI: 10.1097/FPC.0000000000000024.
86. Sung C, Lee PL, Tan LL., et al. Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority. Drug Saf. 2011; 34: 1167-1175. DOI: 10.2165/11594440-000000000-00000.
87. Premawardhena A, Fisher CA, Liu YT. et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis. 2003; 31: 98-101.
88. Wang L-Z, Ramírez J, Yeo W., et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8: e54522. DOI: 10.1371/journal.pone.0054522.
89. Han J-Y, Lim H-S, Shin ES., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006; 24: 2237-2244. DOI: 10.1200/JCO.2005.03.0239.
90. Yamanaka H, Nakajima M, Katoh M., et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9 22) and its effects on the transcriptional activity. Pharmacogenetics. 2004; 14: 329-332.
91. Yuan H-Y, Chen-J-J, Lee MTM., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005; 14: 1745-1751. DOI: 10.1093/hmg/ddi180.
92. Sandanaraj E, Lal S, Selvarajan V., et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res. 2008; 14: 7116-7126. DOI: 10.1158/1078-0432.CCR-08-0411.
93. Tham L-S, Holford NHG, Hor S-Y., et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res. 2007; 13: 7126-7132. DOI: 10.1158/1078-0432.CCR-07-1276.
94. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci. 2005; 94: 1169-1186. DOI: 10.1002/jps.20324.
95. Tsuchiya Y, Nakajima M, Takagi S., et al. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006; 66: 9090-9098. DOI: 10.1158/0008-5472.CAN-06-1403.
96. Edwards SL, Beesley J, French JD., et al. Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet. 2013; 93: 779-797. DOI: 10.1016/j.ajhg.2013.10.012.
97. Bernstein BE, Birney E, Dunham I., et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489: 57-74. DOI: 10.1038/nature11247.
98. Syn NLX, Lee S-C, Brunham LR., et al. Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation. Pharmacogenet Genomics. 2015;25:491-500. DOI: 10.1097/FPC.0000000000000165.
99. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev. 2002; 11: 505-512.